AR126955A1 - CGRP ANTAGONISTS FOR THE TREATMENT OF SKIN CONDITIONS - Google Patents

CGRP ANTAGONISTS FOR THE TREATMENT OF SKIN CONDITIONS

Info

Publication number
AR126955A1
AR126955A1 ARP220102367A ARP220102367A AR126955A1 AR 126955 A1 AR126955 A1 AR 126955A1 AR P220102367 A ARP220102367 A AR P220102367A AR P220102367 A ARP220102367 A AR P220102367A AR 126955 A1 AR126955 A1 AR 126955A1
Authority
AR
Argentina
Prior art keywords
skin conditions
treatment
formula
methods
cgrp antagonists
Prior art date
Application number
ARP220102367A
Other languages
Spanish (es)
Inventor
Robert Croop
Daniel Franjic
Original Assignee
Biohaven Pharm Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharm Holding Co Ltd filed Critical Biohaven Pharm Holding Co Ltd
Publication of AR126955A1 publication Critical patent/AR126955A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Abstract

Se proporcionan métodos de tratamiento de condiciones de la piel con uno o más antagonistas de receptores de CGRP y/o sus composiciones farmacéuticas. Tales métodos son útiles para tratar, mejorar, aliviar, proporcionar profilaxis o prevención, detener la progresión y/o reducir el riesgo de una o más condiciones de la piel en un sujeto mamífero, tal como un humano. En particular, los antagonistas del receptor de CGRP tales como aquellos de la fórmula (1), fórmula (2) y/o fórmula (3) como se describen en el presente documento son de utilidad en métodos de tratamiento de condiciones de la piel en un sujeto que lo necesita.Methods of treating skin conditions with one or more CGRP receptor antagonists and/or their pharmaceutical compositions are provided. Such methods are useful for treating, improving, alleviating, providing prophylaxis or prevention, arresting the progression and/or reducing the risk of one or more skin conditions in a mammalian subject, such as a human. In particular, CGRP receptor antagonists such as those of formula (1), formula (2) and/or formula (3) as described herein are useful in methods of treating skin conditions in a subject who needs it.

ARP220102367A 2021-09-02 2022-09-01 CGRP ANTAGONISTS FOR THE TREATMENT OF SKIN CONDITIONS AR126955A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163240071P 2021-09-02 2021-09-02

Publications (1)

Publication Number Publication Date
AR126955A1 true AR126955A1 (en) 2023-12-06

Family

ID=85412859

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102367A AR126955A1 (en) 2021-09-02 2022-09-01 CGRP ANTAGONISTS FOR THE TREATMENT OF SKIN CONDITIONS

Country Status (2)

Country Link
AR (1) AR126955A1 (en)
WO (1) WO2023034467A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044043B2 (en) * 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
US20210121541A1 (en) * 2019-07-05 2021-04-29 Allergan Pharmaceuticals International Limited CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders

Also Published As

Publication number Publication date
WO2023034467A3 (en) 2023-04-13
WO2023034467A2 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
CL2021001292A1 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
CL2019002255A1 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides.
MX2020004467A (en) Methods for treating or preventing asthma by administering an il-4r antagonist.
DOP2017000097A (en) COMPOSITIONS AND METHODS OF USE TO TREAT METABOLIC DISORDERS
CO2020010956A2 (en) Compositions and methods for the treatment of cancer and immune disorders using veillonella bacteria
CR20190376A (en) Subcutaneous her2 antibody formulations
ECSP22061711A (en) N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES RELATED THERETO
CL2020001990A1 (en) Spiro-lactam nmda receptor modulators and their uses. (Sr. 1991-20)
CL2019003076A1 (en) Dosage regimen for the treatment of cognitive and motor impairments with blood plasma and blood plasma products.
BR112021025676A2 (en) Compositions and methods for treating a th2-mediated condition with the use of prevotella
BR112018070852A2 (en) selenium disulfide compositions for use in the treatment of meibomian gland dysfunction
PE20210455A1 (en) SPIRO-LACTAMA NMDA RECEIVER MODULATORS AND USES OF THEM
CR20170085A (en) ADJUNCTIVE THERAPY WITH 25-HYDROXY VITAMIN D
CL2017001301A1 (en) Stabilized ophthalmic compositions of omega 3
CL2019001658A1 (en) Tricyclic enone pyrimidine derivatives for rory inhibition and other uses.
CO2021014008A2 (en) Pharmaceutical Compounds for the Treatment of Complement-Mediated Disorders
MX2020004810A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases.
CL2021001656A1 (en) Imidazopyridine and imidazopyridine compounds and their uses.
CL2019000625A1 (en) Fxr agonist combination.
CO2021000945A2 (en) Dosage regimen for the treatment of cognitive and motor impairments with blood plasma and blood plasma products
CL2019001014A1 (en) Methods of treating inflammation-related conditions using pluripotent anti-inflammatory and metabolic modulators.
CO2020004034A2 (en) Methods for the treatment of muscular dystrophy
MX2020004678A (en) Use of riluzole prodrugs to treat ataxias.
ECSP21003718A (en) TRIAZOLQUINOXALINE DERIVATIVES ADDITIONALLY SUBSTITUTED
PH12021550122A1 (en) Solubilized apyrases, methods and use

Legal Events

Date Code Title Description
FB Suspension of granting procedure